These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9106567)

  • 1. Quality control of spirometry testing in the registry for patients with severe alpha1-antitrypsin deficiency. alpha1-Antitrypsin Deficiency Registry Study Group.
    Stoller JK; Buist AS; Burrows B; Crystal RG; Fallat RJ; McCarthy K; Schluchter MD; Soskel NT; Zhang R
    Chest; 1997 Apr; 111(4):899-909. PubMed ID: 9106567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group.
    Am J Respir Crit Care Med; 1998 Jul; 158(1):49-59. PubMed ID: 9655706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT).
    Esquinas C; Serreri S; Barrecheguren M; Rodriguez E; Nuñez A; Casas-Maldonado F; Blanco I; Pirina P; Lara B; Miravitlles M
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1001-1007. PubMed ID: 29615836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. alpha 1-Antitrypsin Deficiency Registry Study Group.
    Turino GM; Barker AF; Brantly ML; Cohen AB; Connelly RP; Crystal RG; Eden E; Schluchter MD; Stoller JK
    Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1718-25. PubMed ID: 8970361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spirometry in the Lung Health Study. 1. Methods and quality control.
    Enright PL; Johnson LR; Connett JE; Voelker H; Buist AS
    Am Rev Respir Dis; 1991 Jun; 143(6):1215-23. PubMed ID: 2048803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asthma features in severe alpha1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry.
    Eden E; Hammel J; Rouhani FN; Brantly ML; Barker AF; Buist AS; Fallat RJ; Stoller JK; Crystal RG; Turino GM
    Chest; 2003 Mar; 123(3):765-71. PubMed ID: 12628876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ICS Use May Modify FEV1 Decline in α1-Antitrypsin Deficiency Patients with Relatively High Blood Eosinophils.
    Low EV; Hughes SM; Zaffarullah S; Kantas D; Stockley RA; Turner AM
    Respiration; 2018; 95(2):114-121. PubMed ID: 29253843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry.
    Rahaghi FF; Monk R; Ramakrishnan V; Beiko T; Strange C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():3193-3199. PubMed ID: 33299307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group.
    McElvaney NG; Stoller JK; Buist AS; Prakash UB; Brantly ML; Schluchter MD; Crystal RD
    Chest; 1997 Feb; 111(2):394-403. PubMed ID: 9041988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial of standard versus modified expiration to achieve end-of-test spirometry criteria.
    Stoller JK; Basheda S; Laskowski D; Goormastic M; McCarthy K
    Am Rev Respir Dis; 1993 Aug; 148(2):275-80. PubMed ID: 8342888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events.
    Stoller JK; Fallat R; Schluchter MD; O'Brien RG; Connor JT; Gross N; O'Neil K; Sandhaus R; Crystal RG
    Chest; 2003 May; 123(5):1425-34. PubMed ID: 12740257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis.
    Silverman EK; Chapman HA; Drazen JM; Weiss ST; Rosner B; Campbell EJ; O'DONNELL WJ; Reilly JJ; Ginns L; Mentzer S; Wain J; Speizer FE
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1770-8. PubMed ID: 9620904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV
    Fähndrich S; Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R
    Respir Med; 2017 Aug; 129():8-15. PubMed ID: 28732839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decline in FEV1 among patients with severe hereditary alpha 1-antitrypsin deficiency type PiZ.
    Seersholm N; Kok-Jensen A; Dirksen A
    Am J Respir Crit Care Med; 1995 Dec; 152(6 Pt 1):1922-5. PubMed ID: 8520756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acceptability and reproducibility criteria of the American Thoracic Society as observed in a sample of the general population.
    Hankinson JL; Bang KM
    Am Rev Respir Dis; 1991 Mar; 143(3):516-21. PubMed ID: 2001060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?
    Stockley RA; Edgar RG; Pillai A; Turner AM
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1745-56. PubMed ID: 27536086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Obstructive Pulmonary Disease Early Intervention Trial (Lung Health Study). Baseline characteristics of randomized participants.
    Buist AS; Connett JE; Miller RD; Kanner RE; Owens GR; Voelker HT
    Chest; 1993 Jun; 103(6):1863-72. PubMed ID: 8404115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.
    Seersholm N; Wencker M; Banik N; Viskum K; Dirksen A; Kok-Jensen A; Konietzko N
    Eur Respir J; 1997 Oct; 10(10):2260-3. PubMed ID: 9387950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ).
    Piitulainen E; Eriksson S
    Eur Respir J; 1999 Feb; 13(2):247-51. PubMed ID: 10065663
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.